Development of Nasal Vaccine agaisnt RS virus based on neonatal innate immunity

2016 Fiscal Year Final Research Report

• Project/Area Number: 26670514
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Embryonic/Neonatal medicine
• Research Institution: Osaka City University
• Principal Investigator: Saito Mika 大阪市立大学, 大学院医学研究科, 講師 (40419700)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ワクチン / アジュバント / 新生児 / 自然免疫 / RSウイルス

Outline of Final Research Achievements

Adjuvant is necessary for the development of vaccine against RSV, because the immune response against recombinant RSV protein is weak in neonates and adults. Zymosan, a cell wall extract from Saccharomyces cervisiae, gave comparable innate immune response via TLR2/TLR6 heterodimer in the immune cells of cord blood and adult blood, thus may be useful as a nasal vaccine adjuvant against RSV in neonates and infants.

Free Research Field

新生児